In this webinar, learn more about the ongoing research and clinical trials to manage acute respiratory distress syndrome (ARDS) in COVID-19 patients. Two experts will share their extensive experience with therapies using mesenchymal stem cells (MSCs) and the small extracellular vesicles (sEVs) that MSCs produce as potential treatments for COVID-19 patients with ARDS.
What will you learn?
- Explore how sEVs can recapitulate the therapeutic effect of MSCs
- Discuss clinical trial design with critically ill patients, such as those with COVID-19, including strategies for optimizing sample size, managing patient and disease heterogeneity, and maximizing the use of trial data
- Learn how the lung inflammatory environment may alter MSC behavior
Who may this interest?
- Cell therapy manufacturers